Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on Capital EmployedReturn on Invested CapitalTimes Interest Earned

Lifecore Biomedical, Inc. \De\ (LFCR) EBIT Margin (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported EBIT Margin over the past 16 years, most recently at 14.62% for Q2 2025.

  • For Q2 2025, EBIT Margin rose 894.0% year-over-year to 14.62%; the TTM value through May 2025 reached 13.38%, down 649.0%, while the annual FY2025 figure was 13.38%, 649.0% down from the prior year.
  • EBIT Margin for Q2 2025 was 14.62% at Lifecore Biomedical, Inc. \De\, up from 25.68% in the prior quarter.
  • Over five years, EBIT Margin peaked at 14.62% in Q2 2025 and troughed at 46.89% in Q3 2024.
  • A 5-year average of 12.42% and a median of 11.37% in 2022 define the central range for EBIT Margin.
  • Biggest five-year swings in EBIT Margin: surged 2784bps in 2021 and later tumbled -3889bps in 2022.
  • Year by year, EBIT Margin stood at 14.41% in 2021, then tumbled by -270bps to 24.48% in 2022, then soared by 80bps to 4.92% in 2023, then dropped by -22bps to 6.02% in 2024, then skyrocketed by 343bps to 14.62% in 2025.
  • Business Quant data shows EBIT Margin for LFCR at 14.62% in Q2 2025, 25.68% in Q1 2025, and 6.02% in Q4 2024.